258 related articles for article (PubMed ID: 32302426)
21. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
22. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.
Crump M; Kuruvilla J; Couban S; MacDonald DA; Kukreti V; Kouroukis CT; Rubinger M; Buckstein R; Imrie KR; Federico M; Di Renzo N; Howson-Jan K; Baetz T; Kaizer L; Voralia M; Olney HJ; Turner AR; Sussman J; Hay AE; Djurfeldt MS; Meyer RM; Chen BE; Shepherd LE
J Clin Oncol; 2014 Nov; 32(31):3490-6. PubMed ID: 25267740
[TBL] [Abstract][Full Text] [Related]
23. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
Manconi L; Coviello E; Canale F; Giannoni L; Minetto P; Guolo F; Clavio M; Marcolin R; Cea M; Cagnetta A; Gobbi M; Miglino M; Ballerini F; Lemoli RM
Leuk Lymphoma; 2020 Jan; 61(1):84-90. PubMed ID: 31480933
[TBL] [Abstract][Full Text] [Related]
24. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
25. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
[TBL] [Abstract][Full Text] [Related]
26. Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.
Schirmbeck NG; Mey UJ; Olivieri A; Ko YD; Kaiser U; Flieger D; Witzens-Harig M; Schmidt-Wolf IG
Cancer Invest; 2016 Sep; 34(8):361-72. PubMed ID: 27635469
[TBL] [Abstract][Full Text] [Related]
27. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
Chau I; Webb A; Cunningham D; Hill M; Rao S; Ageli S; Norman A; Gill K; Howard A; Catovsky D
Br J Haematol; 2001 Dec; 115(4):786-92. PubMed ID: 11843810
[TBL] [Abstract][Full Text] [Related]
28. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
[TBL] [Abstract][Full Text] [Related]
29. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone.
Simpson L; Ansell SM; Colgan JP; Habermann TM; Inwards DJ; Ristow KM; Johnston PB; Markovic SN; Micallef IN; Porrata LF; Witzig TE
Leuk Lymphoma; 2007 Jul; 48(7):1332-7. PubMed ID: 17613762
[TBL] [Abstract][Full Text] [Related]
31. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Hagberg H; Gisselbrecht C;
Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
[TBL] [Abstract][Full Text] [Related]
32. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S; Beldi-Ferchiou A; Alcantara M; Cacheux V; Safar V; Burroni B; Guidez S; Gastinne T; Canioni D; Thieblemont C; Maisonneuve H; Bodet-Milin C; Houot R; Oberic L; Bouabdallah K; Bescond C; Damaj G; Jaccard A; Daguindau N; Moreau A; Tilly H; Ribrag V; Delfau-Larue MH; Hermine O; Macintyre E
Lancet Haematol; 2020 Nov; 7(11):e798-e807. PubMed ID: 32971036
[TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
[TBL] [Abstract][Full Text] [Related]
34. Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas.
Kroschinsky F; Röllig D; Riemer B; Kramer M; Ordemann R; Schetelig J; Bornhäuser M; Ehninger G; Hänel M
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3067-3073. PubMed ID: 31563974
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.
Ueda K; Nannya Y; Asai T; Yamamoto G; Hangaishi A; Takahashi T; Imai T; Kurokawa M
J Chemother; 2010 Feb; 22(1):54-7. PubMed ID: 20227994
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Bieker R; Kessler T; Berdel WE; Mesters RM
Oncol Rep; 2003; 10(6):1915-7. PubMed ID: 14534718
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
38. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation.
Press OW; Livingston R; Mortimer J; Collins C; Appelbaum F
J Clin Oncol; 1991 Mar; 9(3):423-31. PubMed ID: 1999711
[TBL] [Abstract][Full Text] [Related]
39. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.
Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T
Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
